Peptide Conjugate CDMO Services

Peptide Conjugate Services

Sophia provides peptide conjugate CDMO services for sponsors developing peptide-drug conjugates, peptide-radionuclide conjugates, peptide-oligonucleotide conjugates, peptide-lipid conjugates, peptide-polymer conjugates, PEGylated peptides, diagnostic peptide conjugates, cell-penetrating peptide systems, receptor-targeted peptides, antimicrobial peptide conjugates, immune-modulating peptides, and next-generation targeted delivery products.

Peptides sit in a useful middle zone. They are smaller than antibodies, more sequence-defined than many biologics, more biologically expressive than most small molecules, and often able to bind receptors, enter tissues, carry payloads, trigger signalling, block interactions, or guide delivery. Add conjugation, and the peptide becomes a targeted product system: peptide plus linker, peptide plus drug, peptide plus chelator, peptide plus lipid, peptide plus oligonucleotide, peptide plus polymer, peptide plus dye, peptide plus delivery motif.

That is where the technical difficulty begins. A peptide conjugate is not just a peptide with something attached. The conjugation site changes behaviour. The linker changes stability. The payload changes solubility. The peptide may oxidise, aggregate, racemise, hydrolyse, deamidate, or bind surfaces. The final product may require high-purity preparative HPLC, LC-MS confirmation, residual reagent control, counterion strategy, formulation screening, sterile product interface, and stability testing.

Sophia’s peptide conjugate CDMO services support peptide sequence review, solid-phase peptide synthesis interface, linker strategy, conjugation chemistry, payload attachment, chelator installation, lipidation, PEGylation, peptide-oligonucleotide conjugation, purification, desalting, lyophilisation, LC-MS analytics, impurity profiling, formulation, stability, GMP/GMP-like documentation, and scale-up through a European technical model supported by state-of-the-art facilities in Spain and Switzerland.

The goal is to turn a peptide sequence into a controlled conjugated product with defined identity, purity, activity, stability, and manufacturability.

Why Peptide Conjugates Matter

Peptide conjugates matter because peptides can recognise biology with a precision that is difficult to reproduce with ordinary small molecules, while remaining far smaller and often more chemically tunable than antibodies. A peptide may bind a receptor, mimic a hormone, block a protein interaction, target a tumour-associated receptor, penetrate cells, bind membranes, carry a diagnostic label, deliver an oligonucleotide, or bring a radionuclide to a target tissue.

Conjugation expands that utility. A peptide can be linked to:

Cytotoxic small molecule payloads
Chelators for radioligand therapy or imaging
Fluorescent dyes
Oligonucleotides
siRNA
Lipids
PEG chains
Albumin-binding groups
Cell-penetrating motifs
Antimicrobial groups
Polymers
Nanoparticle anchors
Immune-stimulating motifs
Diagnostic labels

This makes peptide conjugates relevant across oncology, nuclear medicine, metabolic disease, diagnostics, genetic medicine, antimicrobial development, imaging, drug delivery, and research tools.

But the same flexibility creates complexity. A short peptide can become difficult after conjugation. A hydrophobic payload may make it insoluble. A lipid may increase aggregation. A chelator may change receptor binding. A PEG chain may improve half-life but reduce potency. An oligonucleotide may create a highly charged hybrid molecule. A dye may alter biodistribution. A linker may be chemically elegant but biologically unstable.

A serious peptide Conjugate CDMO services programme must therefore treat the conjugate as a new molecule, not an accessory version of the original peptide.

A Longer History of Peptides and Peptide Conjugates

Peptide therapeutics began with biology’s own language. Insulin, oxytocin, vasopressin, glucagon, somatostatin, and many other peptide hormones showed that short amino acid chains could control powerful physiological systems. The early peptide era was not glamorous in the modern platform sense. It was extraction, purification, animal tissue, physiology, and clinical need. Insulin turned a lethal disease into a manageable condition and proved that a peptide could be a serious medicine.

Then chemistry changed the field. Solid-phase peptide synthesis made it possible to build peptides stepwise on a resin, washing away excess reagents between cycles and releasing the final chain after assembly. That idea sounds ordinary now, but it was one of the great practical turns in medicinal chemistry. Peptides moved from biological isolates to designed sequences. Chemists could alter residues, protect functional groups, introduce non-natural amino acids, cyclise chains, add disulphides, attach labels, and explore structure-activity relationships with much more control.

The next phase made peptides more durable and more drug-like. Natural peptides often degrade quickly. Enzymes cut them. Kidneys clear them. Formulations stress them. Developers responded with D-amino acids, N-methylation, cyclisation, lipidation, PEGylation, terminal capping, stapling, backbone modification, depot formulations, albumin-binding groups, and other half-life extension tools. The peptide was no longer only a short biological signal. It became a chemically engineered pharmacological object.

Peptide conjugates emerged from that engineering mindset. In nuclear medicine, receptor-targeted peptides linked to chelators enabled imaging and radioligand therapy.

Somatostatin analogues, bombesin-related ligands, integrin-binding peptides, and other receptor-targeted systems helped show how peptides could guide radioisotopes. In oncology, peptide-drug conjugates explored whether smaller targeting ligands could deliver cytotoxic payloads without relying on full antibodies. In diagnostics, dye-labelled peptides became useful tools for imaging, binding studies, and assay development.

In genetic medicine, peptide-oligonucleotide and peptide-siRNA conjugates opened routes for delivery and cellular uptake. In drug delivery, cell-penetrating peptides and receptor-targeted peptides became molecular passports, sometimes brilliant, sometimes overpromised, always technically interesting.

The creative arc is clear. Peptides started as biological messages. Chemistry made them buildable. Conjugation made them carriers. Modern development now asks whether they can be made cleanly, scaled, formulated, stabilised, and documented with the same seriousness as other advanced modalities.

That is the territory for peptide conjugate CDMO services: not peptide nostalgia, but controlled peptide engineering.

The Chemistry of Peptide Conjugates

A peptide conjugate contains at least three design elements: the peptide, the linker or attachment chemistry, and the conjugated group. Each part can affect the final product.

The peptide provides recognition, activity, structure, or delivery. It may be linear, cyclic, stapled, disulphide-rich, D-amino-acid-containing, N-methylated, C-terminally amidated, N-terminally acetylated, lipidated, PEGylated, or modified with non-natural residues. Its sequence determines binding, solubility, degradation, charge, hydrophobicity, and synthesis difficulty.

The linker controls distance, flexibility, cleavage, stability, hydrophilicity, and release. Linkers may be stable or cleavable. They may respond to enzymes, pH, redox conditions, hydrolysis, or intracellular processing. They may contain PEG units, alkyl chains, amino acid spacers, self-immolative groups, hydrophilic handles, or steric spacers.

The conjugated group defines the product’s extra function. A cytotoxic payload creates a peptide-drug conjugate. A chelator creates a radiopharmaceutical precursor. A dye creates an imaging or diagnostic conjugate. A lipid can extend half-life or support membrane interaction. An oligonucleotide creates a hybrid delivery molecule. PEG can extend circulation and alter solubility. A polymer can change biodistribution or depot behaviour.

The attachment chemistry may involve amines, thiols, azides, alkynes, maleimides, NHS esters, oximes, hydrazones, click chemistry, cysteine conjugation, lysine conjugation, N-terminal conjugation, C-terminal conjugation, side-chain installation, enzymatic ligation, or orthogonal protecting group strategy.

A peptide conjugate is a small molecule by mass compared with an antibody, but it can be chemically dense. That density is why analytical control matters.

Peptide Conjugate Product Types Supported

Sophia supports Peptide Conjugate CDMO Services across therapeutic, diagnostic, research, and advanced delivery programmes.

Peptide-drug conjugates may include receptor-targeted peptides linked to cytotoxic payloads, immune-modulating small molecules, antimicrobial agents, enzyme inhibitors, or intracellular payloads. These products require payload attachment, linker stability, purity, potency, solubility, and safety strategy.

Peptide-radionuclide conjugates may include peptide-chelator precursors for Lu-177, Ga-68, Cu-64, Ac-225, Zr-89, Tc-99m, and other isotopes. These products require chelator installation, metal-binding performance, radiolabelling compatibility, impurity control, and formulation strategy.

Peptide-oligonucleotide conjugates may include peptide-ASO, peptide-siRNA, peptide-PMO, peptide-PNA, peptide-guide RNA, or peptide-aptamer products. These require control of peptide identity, oligo identity, conjugation efficiency, purification, charge behaviour, and stability.

Peptide-lipid conjugates may include lipidated peptides, albumin-binding peptides, long-acting peptide products, GLP-1-style lipidated concepts, membrane-targeting peptides, and nanoparticle-anchor peptides.

PEGylated peptide products may include half-life extended peptides, solubility-enhanced peptides, depot-adjacent products, and immune-modulating formats.

Diagnostic peptide conjugates may include dye-labelled peptides, biotinylated peptides, fluorescent probes, PET/SPECT precursors, affinity reagents, and assay controls.

Cell-penetrating and delivery peptides may include TAT-like motifs, arginine-rich peptides, receptor-targeted delivery peptides, endosomal escape peptides, and conjugates designed to improve intracellular access.

Each product type has a different control strategy. The shared requirement is that peptide, linker, and conjugated group must be understood as one final molecule.

Peptide Sequence and Developability Review

Sophia supports peptide sequence and developability review before conjugation scale-up. This includes sequence length, charge, hydrophobicity, solubility, aggregation risk, oxidation risk, methionine and cysteine liabilities, deamidation risk, aspartimide formation, racemisation risk, cleavage-sensitive motifs, non-natural amino acids, cyclisation, disulphide pairing, conjugation site selection, and synthesis feasibility.

Some peptides look simple but manufacture badly. Hydrophobic peptides may aggregate during synthesis or purification. Cysteine-containing peptides may form incorrect disulphides. Long peptides may accumulate deletion impurities. Aspartic acid-containing sequences may form aspartimide under certain conditions. Methionine may oxidise. Glutamine or asparagine may deamidate. Basic peptides may bind surfaces. Arginine-rich peptides may be difficult to purify cleanly.

Conjugation can intensify these issues. A hydrophobic payload can make a marginal peptide insoluble. A lipid can produce sticky materials. A large oligonucleotide can create charge-dominated purification behaviour. A chelator can shift metal binding and analytical profile. A dye can introduce photostability issues.

A strong Peptide Conjugate CDMO Services programme reviews the peptide as a future conjugate, not merely as a standalone sequence.

Solid-Phase Peptide Synthesis Interface

Sophia supports solid-phase peptide synthesis interface planning for peptide conjugate programmes, including resin selection, protecting group strategy, coupling methods, difficult sequence management, non-natural amino acid incorporation, orthogonal handles, terminal modification, cleavage, deprotection, crude peptide assessment, and purification planning.

Most peptide drug substances begin with solid-phase peptide synthesis. Amino acids are added stepwise to a resin-bound chain. Protecting groups prevent unwanted reactions. After assembly, the peptide is cleaved from the resin and deprotected. The crude peptide then undergoes purification and characterisation.

For peptide conjugates, synthesis may include handles for downstream conjugation. These may include azides, alkynes, cysteine residues, lysine side-chain handles, N-terminal amines, C-terminal functional groups, orthogonally protected side chains, chelator-ready motifs, lipidation sites, or protected reactive groups.

The synthesis route should anticipate the final conjugate. Installing the handle at the wrong site can reduce activity. Choosing the wrong protecting group can complicate deprotection. A cleavage condition can damage sensitive groups. A purification route that works for the peptide may not work after conjugation.

Peptide synthesis is the foundation. Conjugation exposes whether the foundation was built properly.

Linker and Payload Strategy

Sophia supports linker and payload strategy for peptide conjugate products. This includes linker length, spacer chemistry, cleavable versus non-cleavable design, hydrophilicity, payload potency, solubility, release mechanism, plasma stability, intracellular processing, receptor binding impact, and manufacturability.

For peptide-drug conjugates, payload selection must match target biology. A high-potency cytotoxic payload may be needed for oncology, but it brings safety and HPAPI handling questions. A stable linker may reduce premature release, while a cleavable linker may improve intracellular payload liberation. A hydrophobic payload may require solubilising linker elements. The payload must not destroy peptide binding.

For peptide-radionuclide conjugates, the chelator-linker system must support radiolabelling and in vivo stability. The linker may affect biodistribution, kidney uptake, tumour retention, and clearance. For peptide-oligonucleotide conjugates, linker chemistry must preserve both nucleic acid function and peptide-mediated delivery. For PEGylated peptides, PEG size and attachment site can alter potency and half-life.

The linker is not passive. It is the hinge where biology and chemistry negotiate.

Conjugation Chemistry Development

Sophia provides Peptide Conjugate CDMO Services for conjugation process development. This may include site-specific conjugation, N-terminal conjugation, cysteine conjugation, lysine conjugation, click chemistry, maleimide-thiol chemistry, oxime ligation, hydrazone formation, NHS ester coupling, activated ester chemistry, enzymatic ligation, chelator coupling, lipidation, PEGylation, and peptide-oligonucleotide conjugation.

Conjugation development must control reaction conversion, site specificity, over-conjugation, under-conjugation, hydrolysis, side reactions, residual linker, residual payload, residual catalyst, stereochemical integrity, oxidation, aggregation, and final purity.

Reaction conditions matter. pH can alter selectivity. Solvent can affect solubility and peptide stability. Temperature can change reaction rate and degradation. Stoichiometry affects conversion and impurity burden. Reaction time can create side products. Metal catalysts may require residual testing. Light-sensitive payloads may require protection. Thiol chemistry may require oxygen control.

The process has to be reproducible. A conjugate made once in a discovery lab is not yet a manufacturable product.

Peptide-Oligonucleotide Conjugates

Sophia supports peptide-oligonucleotide conjugate development, including peptide-ASO, peptide-siRNA, peptide-PMO, peptide-PNA, peptide-aptamer, peptide-guide RNA, and peptide-diagnostic oligo products.

These products combine two chemically different worlds. The peptide may be hydrophobic, cationic, cyclic, or receptor-targeted. The oligonucleotide is highly charged, sequence-defined, and impurity-sensitive. The conjugate may have unusual chromatographic behaviour, complex mass, strong surface binding, and formulation challenges.

Manufacturing may require separate synthesis and purification of peptide and oligo components, activation of one component, conjugation, purification of conjugate from unreacted peptide and oligo, desalting, counterion control, lyophilisation, and stability testing.

Analytics may include LC-MS, ion-exchange HPLC, reverse-phase HPLC, capillary electrophoresis, UV spectroscopy, peptide mapping-style digestion where appropriate, oligo identity testing, and conjugate purity assessment.

Peptide-oligonucleotide conjugates are powerful because they can improve delivery or targeting. They are difficult because neither peptide analytics nor oligo analytics alone fully describe the final product.

Peptide-Radionuclide and Chelator Conjugates

Sophia supports peptide-chelator conjugates for radiopharmaceutical development. These products may act as precursors for radiolabelling with Lu-177, Ga-68, Cu-64, Ac-225, Zr-89, Tc-99m, or other radionuclides.

Development may include chelator selection, linker placement, peptide binding preservation, metal-free manufacturing conditions, trace metal control, reference standard strategy, radiolabelling feasibility, radiochemical purity testing, formulation compatibility, and stability.

Chelators such as DOTA, NOTA, NODAGA, DFO, macropa-like systems, and other structures may be selected based on isotope. The chelator must hold the radionuclide under labelling and biological conditions. The peptide must still bind the target after chelator installation. The final precursor must be pure enough for radiolabelling and stable enough for storage.

Peptide radioligands are where peptide chemistry meets isotope physics. The conjugate has to satisfy both.

Peptide-Lipid and Half-Life Extension Conjugates

Sophia supports peptide-lipid, albumin-binding, PEGylated, and half-life extension conjugates. These may include fatty acid-modified peptides, albumin-binding moieties, PEG chains, polymer conjugates, lipid anchors, cholesterol conjugates, and depot-adjacent peptide systems.

Half-life extension can improve dosing frequency and exposure, but it can also reduce receptor potency, change distribution, increase aggregation, or complicate purification. Lipidated peptides may bind albumin, interact with membranes, or increase hydrophobicity. PEGylation may increase size and solubility but can reduce receptor interaction if poorly placed. Polymer conjugates may alter viscosity, analytics, and formulation.

These products need careful attachment-site selection. A lipid near the receptor-binding region may damage potency. A PEG chain may block the active face. A fatty acid may improve half-life but reduce solubility. Analytical methods must distinguish product-related variants and residual unconjugated peptide.

A long-acting peptide is not just a peptide made heavier. It is a pharmacokinetic design.

Purification and Isolation

Sophia supports purification for peptide conjugates, including preparative reverse-phase HPLC, ion-exchange chromatography, hydrophobic interaction approaches, size-based methods, ultrafiltration/diafiltration, desalting, lyophilisation, polishing, counterion exchange, and impurity removal.

Purification strategy depends on molecular properties. Hydrophobic peptide-drug conjugates may require reverse-phase methods and careful solvent control. Highly charged peptide-oligonucleotide conjugates may require ion-exchange or hybrid approaches. PEGylated peptides may require size or polarity-based separation. Radioligand precursors may need very high purity and trace-metal control. Dye-labelled peptides may require light-sensitive handling.

Impurities may include deletion peptides, truncated peptides, oxidised peptides, deamidated peptides, epimers, unconjugated peptide, unconjugated payload, hydrolysed linker, over-conjugated species, under-conjugated species, residual solvents, residual catalysts, protecting group remnants, and counterion-related materials.

The purification method must be scalable and stability-aware. A harsh method that purifies beautifully but degrades the conjugate is not a good method.

Analytical Development and Characterisation

Sophia’s peptide conjugate CDMO services include analytical development for identity, purity, impurity profile, mass confirmation, sequence confirmation, conjugation site, conjugation efficiency, payload content, residual free payload, residual linker, residual catalyst, counterion, water content, residual solvent, endotoxin where relevant, bioburden or sterility strategy where relevant, and stability.

Methods may include LC-MS, HRMS, UPLC, HPLC, preparative HPLC analytics, ion-exchange HPLC, capillary electrophoresis, amino acid analysis, peptide mapping, NMR for selected structural questions, UV spectroscopy, fluorescence assays for labelled products, ICP-MS for metals, Karl Fischer water testing, residual solvent testing, endotoxin testing, and product-specific potency or binding assays.

The analytical package must match the product type. A peptide-radionuclide precursor may need chelation and metal impurity controls. A peptide-drug conjugate may need free payload testing. A peptide-oligo conjugate may need both peptide and oligo identity. A PEGylated peptide may need molecular weight distribution. A dye-labelled peptide may need photostability and label content.

The product must be described as the conjugate it is, not as the peptide it used to be.

Binding, Potency, and Functional Testing

Sophia supports binding and potency assay strategy for peptide conjugates. Testing may include receptor binding, cell binding, internalisation, cytotoxicity, enzyme inhibition, antimicrobial activity, cell penetration, radiolabelling performance, imaging probe binding, oligonucleotide delivery, knockdown activity, serum stability, plasma stability, and target-specific activity.

For peptide-drug conjugates, potency may depend on receptor binding, internalisation, linker cleavage, payload release, and cell killing. For peptide-radionuclide conjugates, binding and radiolabelling performance are central. For peptide-oligonucleotide conjugates, potency may require cellular uptake and oligo function. For peptide-lipid conjugates, albumin binding and target potency may both matter.

A conjugate can be chemically correct and biologically weaker than the parent peptide. That is why function must be tested after conjugation. The final molecule gets judged, not the design sketch.

Formulation and Stability

Sophia supports formulation development for peptide conjugates across liquid, frozen, lyophilised, injectable, diagnostic, topical research, oral-adjacent research, and nanoparticle-interface formats.

Stability risks may include oxidation, deamidation, hydrolysis, aggregation, precipitation, adsorption, linker cleavage, payload release, racemisation, disulphide scrambling, photodegradation, metal contamination, peptide backbone cleavage, and counterion-related instability. Formulation variables may include pH, buffer, salt, tonicity, sugars, polyols, surfactants, antioxidants, chelators, preservatives where relevant, cryoprotectants, lyoprotectants, and container closure.

Peptide conjugates can be delicate. Some prefer acidic pH. Some aggregate near neutral pH. Some bind glass or plastic. Some degrade in light. Some oxidise through methionine or tryptophan. Some hydrolyse at the linker. Some conjugates become far less soluble after payload attachment.

Lyophilisation may support stability, but cycle development must preserve purity, reconstitution, potency, residual moisture, and appearance. Liquid formats may be simpler but may require cold storage or strict pH control.

A stable peptide conjugate is engineered. It is not assumed.

Sterile Product and Drug Product Interface

Many peptide conjugates require sterile injectable or diagnostic drug product formats. Sophia supports sterile product interface planning, including sterile filtration feasibility, aseptic processing, vial presentation, lyophilised presentation, prefilled syringe interface where appropriate, container closure compatibility, visual inspection, extractables and leachables, reconstitution, dilution, in-use stability, and clinical supply planning.

Peptide conjugates may adsorb to filters, tubing, stoppers, or glass. Hydrophobic conjugates may stick to surfaces. Radioligand precursors may require metal-free handling. Peptide-drug conjugates may require HPAPI-aware workflows. Diagnostic peptides may require light protection. Sterile filtration must be tested because peptide conjugates can aggregate or lose material during filtration.

Drug product planning should begin early. A pure bulk peptide conjugate is not the same as a usable clinical product.

European Facilities, Spain, and Switzerland

Peptide conjugates require precise chemistry, careful purification, strong analytics, formulation discipline, and documentation that can support advanced development. Sophia’s European execution model, supported by state-of-the-art facilities in Spain and Switzerland, provides a high-discipline technical base for peptide conjugation programmes.

Spain supports applied development, formulation work, and scale-up coordination across complex biological and chemical product types. Switzerland adds a quality-led, precision manufacturing culture suited to analytical characterisation, documentation, and high-value therapeutic programmes. Together, they give Sophia a European identity built around calm execution rather than inflated claims.

For peptide conjugates, that matters. The work has to be properly synthetic, properly analytical, properly formulated, and properly documented. No faff. No mystery peaks. No charming impurity story.

GMP, CMC, and Documentation

Sophia supports GMP/GMP-like and CMC documentation for peptide conjugate CDMO services, including peptide sequence records, synthesis process description, raw material controls, linker records, payload records, conjugation process, purification process, impurity control strategy, analytical methods, specifications, formulation report, stability protocol, batch records, CoA, deviation handling, change control, and tech transfer package.

For peptide-drug conjugates, documentation must address payload control, linker stability, free payload, impurity profile, and potency. For peptide-radionuclide precursors, chelator identity, trace metal control, radiolabelling compatibility, and purity are central. For peptide-oligonucleotide conjugates, both peptide and oligo components must be controlled. For PEGylated or lipidated peptides, conjugation site, molecular distribution, and stability matter.

CMC should make the final conjugate legible: what it is, how it is made, what impurities exist, how it is tested, how it is formulated, and how it remains stable.

Documentation is not a finishing chore. It is part of product control.

Why Sophia for Peptide Conjugate CDMO Services

Sophia supports peptide conjugate programmes through peptide synthesis interface, linker strategy, conjugation chemistry, purification, analytical development, formulation, sterile product interface, European facility execution, and GMP/GMP-like documentation.

The service includes:

Peptide conjugate programme review
Peptide sequence and developability review
Solid-phase peptide synthesis interface
Linker and payload strategy
Cysteine, lysine, N-terminal, C-terminal, and click conjugation support
Peptide-drug conjugate development
Peptide-radionuclide precursor development
Peptide-oligonucleotide conjugate development
Peptide-lipid, PEGylated, and albumin-binding conjugates
Purification, desalting, and lyophilisation
LC-MS, HPLC, CE, UV, residual solvent, and impurity analytics
Binding, potency, and functional assay strategy
Formulation and stability development
Sterile product interface
Spain and Switzerland-linked European technical execution
GMP/GMP-like documentation
Scale-up and tech transfer

The platform is suited to sponsors who need peptide, linker, payload, purification, analytics, formulation, and CMC planning to operate as one controlled development route.

Technical Service Summary

Sophia provides peptide conjugate CDMO services for peptide-drug conjugates, peptide-radionuclide conjugates, peptide-chelator precursors, peptide-oligonucleotide conjugates, peptide-siRNA conjugates, peptide-lipid conjugates, PEGylated peptides, albumin-binding peptides, diagnostic peptide conjugates, dye-labelled peptides, antimicrobial peptide conjugates, cell-penetrating peptide products, and receptor-targeted delivery peptides.

Relevant technical needs include peptide synthesis interface, sequence review, linker design, payload attachment, conjugation chemistry, purification, desalting, lyophilisation, LC-MS, HPLC, impurity profiling, binding assays, potency assays, formulation, sterile product planning, stability, GMP/GMP-like documentation, and scale-up.

The service is intended for products where peptide targeting, conjugation chemistry, product purity, and stability define the development path.

FAQ: Peptide Conjugate CDMO Services

1. What are Peptide Conjugate CDMO Services?

Peptide conjugate CDMO services support development and manufacturing of peptides linked to drugs, chelators, radionuclides, oligonucleotides, lipids, PEG, dyes, polymers, or delivery groups, including conjugation, purification, analytics, formulation, stability, and documentation.

2. What is a peptide conjugate?

A peptide conjugate is a peptide chemically linked to another functional group, such as a drug payload, chelator, lipid, PEG chain, oligonucleotide, dye, or delivery moiety.

3. What types of peptide conjugates can Sophia support?

Sophia supports peptide-drug conjugates, peptide-radionuclide precursors, peptide-oligonucleotide conjugates, peptide-siRNA conjugates, peptide-lipid conjugates, PEGylated peptides, albumin-binding peptides, and diagnostic peptide conjugates.

4. What makes peptide conjugate manufacturing difficult?

Challenges include peptide synthesis, conjugation site control, linker stability, payload solubility, aggregation, purification, free payload removal, impurity profiling, formulation, and stability.

5. What analytics are used for peptide conjugates?

Analytics may include LC-MS, HRMS, HPLC, UPLC, ion-exchange chromatography, capillary electrophoresis, amino acid analysis, UV spectroscopy, residual solvent testing, water testing, endotoxin where relevant, and product-specific potency assays.

6. Can Sophia support peptide-radionuclide conjugates?

Yes. Sophia supports peptide-chelator precursor development for radioligand products, including chelator strategy, conjugation, purification, trace-metal control, radiolabelling compatibility, formulation, and stability.

7. Can Sophia support peptide-oligonucleotide conjugates?

Yes. Sophia supports peptide-oligonucleotide conjugates, including peptide-ASO, peptide-siRNA, peptide-PMO, peptide-PNA, and peptide-aptamer products.

8. Can peptide conjugates be lyophilised?

Yes. Many peptide conjugates can be lyophilised, but cycle development must preserve purity, potency, reconstitution, appearance, residual moisture, and stability.

9. Can peptide conjugates require HPAPI controls?

Yes. Peptide-drug conjugates carrying potent cytotoxic payloads may require HPAPI-aware handling, containment, cleaning strategy, free payload testing, and operator safety controls.

10. What should sponsors provide to begin a peptide conjugate project?

Useful starting information includes peptide sequence, target, conjugation site, linker, payload or conjugated group, intended use, existing synthesis data, purity target, formulation needs, stability goals, scale, and regulatory stage.

Conclusion

Sophia provides peptide conjugate CDMO services for peptide-drug, peptide-radionuclide, peptide-oligonucleotide, peptide-lipid, PEGylated, diagnostic, and targeted delivery programmes.

Peptide conjugates require controlled peptide synthesis, site-aware conjugation, purification, analytical confirmation, formulation, stability, and documentation. The final product must be evaluated as a new conjugated molecule, not as a modified version of the parent peptide.

Email our team at info@sophiacdmo.com